3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Ovarian Neoplasms
5
Fallopian Tube Neoplasms
5
Breast Neoplasms
5
Endometrial Neoplasms
4
Neoplasms
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Prostate Cancer Metastatic
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Mesothelioma, Malignant
1
Leiomyosarcoma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Adenocarcinoma, Clear Cell
1
Adenocarcinoma of the Oesophagus
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
ATM Gene Mutation
1
Interventions
Cisplatin
28
Pemetrexed
24
pembrolizumab
12
Nivolumab
10
Carboplatin
9
atezolizumab
7
Gemcitabine
7
Cyclophosphamide
7
durvalumab
6
Drug Therapy
6
sodium thiosulfate
5
Radiotherapy, Intensity-Modulated
5
tremelimumab
4
aldesleukin
4
Radiotherapy
4
Interleukin-2
4
sargramostim
3
Vinorelbine
3
Platinum
3
Photochemotherapy
3
Ipilimumab
3
Doxorubicin
3
Dihematoporphyrin Ether
3
Chemotherapy, Adjuvant
3
Cerebral Decortication
3
vatalanib
2
regorafenib
2
niraparib
2
lenvatinib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
rucaparib
×
Clear all
NCT03654833
2023-03-14
MiST
University of Leicester
Phase 2
Unknown
186 enrolled